Events

Videos

Podcasts

Articles

PER® New York GU

Mario Sznol, MD, professor of Medicine, Yale Cancer Center, shares how to discuss immunotherapy as a treatment option for patients with renal cell carcinoma (RCC).

When talking to patients regarding their treatment plan, Sznol emphasizes the benefits of immunotherapy, such as durable remissions and a favorable toxicity profile.

Sznol stresses that even if patients do not respond to immunotherapy in the first-line setting, there are still other available therapies that can be used in later lines of therapy.

Mario Sznol, MD, professor of Medicine, Yale Cancer Center, shares how to discuss immunotherapy as a treatment option for patients with renal cell carcinoma (RCC). 


Dr. Sznol on Immunotherapy in Patients With RCC

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting treatment with abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with castration-resistant prostate cancer (CRPC).

There are several factors that influence this decision, Crawford explains. For example, it depends whether patients have previously received anti-androgen therapies or agents such as ketoconazole. Crawford uses both enzalutamide and abiraterone in clinical practice, as well as studies the results of clinical trials investigating both therapies.

Further research is needed on whether using enzalutamide and abiraterone in combination demonstrates strong efficacy in these patients, Crawford adds.

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting abiraterone versus enzalutamide for the treatment of patients with castration-resistant prostate cancer.

PER® New York GU | Conference

Dr. Sznol on Immunotherapy in Patients With RCC

Dr. Crawford on Abiraterone Versus Enzalutamide in Prostate Cancer